港股开盘：恒指跌0.18%、科指跌0.69%，AI应用股走强，有色金属股活跃，科网股、汽车股走势疲软

Market Overview - The Hong Kong stock market opened lower on the first trading day after the holiday, with the Hang Seng Index down 0.18% at 26,657.84 points, the Hang Seng Tech Index down 0.69% at 5,330.61 points, and the National Enterprises Index down 0.19% at 9,052.67 points. The Red Chip Index, however, rose by 0.79% to 4,415.05 points [1] Company Performance Forecasts - Several companies in Hong Kong are facing significant profit declines for 2025. - Stone Four Pharmaceutical Group (02005.HK) expects a net profit of approximately HKD 1.061 billion, a decrease of 45% to 60% year-on-year [2] - Shougang Resources (00639.HK) anticipates a net profit between HKD 600 million to HKD 700 million, reflecting a year-on-year decline of about 53% to 60% [3] - Pearl River Shipping (00560.HK) projects a net profit between HKD 41 million to HKD 55 million, down 53% to 65% year-on-year [4] - Goodbaby International (01086.HK) expects a net profit decline of 35% to 45%, primarily due to reduced gross margins and increased income tax [5] - Hanyuan Holdings (00439.HK) has issued a profit warning, forecasting a net loss of approximately HKD 130 million to HKD 150 million for 2025 [6] - In contrast, China New Town (01278.HK) has issued a profit alert, expecting a net profit of approximately RMB 76 million for 2025 [7] Biopharmaceutical Sector Developments - The biopharmaceutical sector is experiencing positive developments with several new drug approvals. - Fuhong Hanlin (02696.HK) announced that its HLX15-SC (recombinant anti-CD38 fully human monoclonal antibody injection) for treating multiple myeloma has received FDA approval for a Phase 1 clinical trial [8] - CSPC Pharmaceutical Group (01093.HK) has also received FDA approval to conduct clinical trials for its GLP-1/GIP receptor dual agonist long-acting injection [8] - Bokan Vision Cloud-B (02592.HK) reported that its CBT-199 new drug clinical trial application has been approved for safety advancement [8] - Changfeng Pharmaceutical (02652.HK) has been included in the Hang Seng Composite Index, effective in the next index review cycle [9] Stock Buybacks - Xiaomi Group-W (01810.HK) repurchased 1.5 million shares for approximately HKD 54.7041 million, with a buyback price between HKD 36.38 and HKD 36.50 [10] - NetEase Cloud Music (09899.HK) repurchased 92,400 shares for approximately HKD 14.9949 million, with a buyback price between HKD 160.3 and HKD 163.7 [10] - Other companies such as Geely Automobile (00175.HK), Meitu (01357.HK), and Tanwan Games (09890.HK) also engaged in stock buybacks [10] Institutional Insights - Huatai Securities suggests that the current market volatility is high, with key variables influenced by U.S. stock performance, holiday consumption data, and AI technology advancements. They recommend a balanced allocation, focusing on sectors benefiting from AI progress, such as semiconductors, specialty consumption, and electrical equipment [12] - Daiwa Capital Markets notes that the mainland internet healthcare sector is entering a new phase, driven by AI innovation and policy support, despite ongoing profitability challenges [13] - Analysts from ING indicate that the recent decline in gold prices is a corrective pause rather than the start of a deep pullback, with expectations of stronger demand as market liquidity in Asia recovers [13]